Lithium Ion

Lithium Ion

SCHEMBL259962

O=C([O-])CN1CC2CC(=O)Nc3cccc1c32.[Li+]

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CALCRL Q16602 6/20 0.49
ALDH1A1 P00352 5/20 0.39
KDM4E B2RXH2 3/20 0.35
HTT P42858 2/20 0.35
CREBBP Q92793 2/20 0.35
CASP3 P42574 1/20 0.35
CASP2 P42575 1/20 0.35
BRD4 O60885 2/20 0.34
EPHX2 P34913 1/20 0.34
MEN1 O00255 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL261346 0.87 CALCRL (0.49) CALCRLALDH1A1KDM4EHTTCREBBP
Lithium Ion SCHEMBL260924 0.82 CALCRL (0.40) CALCRLALDH1A1CREBBPBRD4
SCHEMBL280579 0.81 CALCRL (0.45) CALCRLALDH1A1CREBBPBRD4EPHX2
SCHEMBL261309 0.75 CALCRL (0.50) CALCRLALDH1A1KDM4EHTTCASP3
SCHEMBL261185 0.73 CALCRL (0.51) CALCRLALDH1A1KDM4EHTTCASP3
SCHEMBL261740 0.70 CALCRL (0.41) CALCRLALDH1A1HTTCREBBPBRD4
SCHEMBL261408 0.69 CALCRL (0.39) CALCRLALDH1A1KDM4EHTTCREBBP
Lithium Ion SCHEMBL260546 0.69 CALCRL (0.51) CALCRLALDH1A1KDM4EHTTCASP3
SCHEMBL13253738 0.69 CALCRL (0.67) CALCRL
SCHEMBL261153 0.68 CALCRL (0.43) CALCRLCASP3CASP2BRD4EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951051-B1 SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2012-10-03 EP disclosed
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 US disclosed
US-8133891-B2 Tricyclic anilide spirolactam CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-03-13 US disclosed
EP-1794146-B1 TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2011-08-03 EP disclosed
US-7968540-B2 Spirohydantoin tricyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-06-28 US disclosed
US-7947677-B2 Spirolactam tricyclic CGRP receptor antagonists MERCK SHARP & DOHME CORP. (US) 2011-05-24 US disclosed